Login to Your Account

Emergent Plans to Diversify and Buy Trubion for $135.5M

By Catherine Hollingsworth

Monday, August 16, 2010
Anthrax vaccine maker Emergent BioSolutions Inc. took steps to expand beyond the realm of biodefense, making plans to buy Seattle-based protein therapeutics specialist Trubion Pharmaceuticals Inc. for approximately $96.8 million up front, plus a potential $38.7 million in milestones for a total potential value of $135.5 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription